10.1152/physiol.00034.2021 50 YohK.HirayamaA.IshizakiK.YamadaA.TakeuchiM.YamagishiS.et al (2008)
Speaker 1 04:21 Were happy to do so Ben and just to be clear, the reason Bill and I wrote the article and we published it is because we believe that there is some promise in Trump RX, but several policy issues have to be resolved before patients can fully embrace and benefit from that promise
Buse JB, Wexler DJ, Tsapas A, et al
FDA approval status Tirzepatide with B6 is not an FDA-approved combination product
The consistency across age groups suggests the drug's mechanism of action (hypothalamic appetite suppression via GLP-1 receptor activation) functions similarly in post-pubertal adolescents and adults
What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care Brandon Aylward Oct 16, 2025 10 min read Few categories in modern medicine have captured the imagination of patients, physicians, and investors as quickly as GLP-1 receptor agonists (GLP-1s)